Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review

European Journal of Medicinal Chemistry
Rajat SarkarTarun Jha

Abstract

Among different Histone deacetylases (HDACs), histone deacetylase 3 (HDAC3) is an epigenetic drug target which is currently marked as a potential therapeutic strategy to combat various cancers. HDAC3 inhibitors are effective for the treatment of cancers, different neurodegenerative disorders, diabetes mellitus, cardiac diseases, HIV, inflammatory diseases, rheumatoid arthritis (RA), etc. Inhibition of HDAC3 metalloenzyme is a dynamic approach for drug design and discovery. This approach has gained considerable interest in recent years. The development of an effective therapeutic agent against HDAC3 is still challenging. A lot of work is still in demand. This current communication is a part of our extended work on HDAC3 inhibitors to achieve deep insight of knowledge about the structural information of HDAC3 inhibitors. This article is unique in terms of detailed structure-activity relationships (SARs) analysis. This may help to find out some important clues to design better active HDAC3 inhibitors in the future.

Citations

Nov 11, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Sravani PulyaBalaram Ghosh
Jan 27, 2021·Chemical Society Reviews·Bo HanJun-Long Li
Dec 4, 2020·International Journal of Molecular Sciences·Yuxiang Luo, Huilin Li
Jun 22, 2020·European Journal of Medicinal Chemistry·Sk Abdul Amin, Tarun Jha
Jul 2, 2020·Journal of Medicinal Chemistry·Terence C S HoA Ganesan
Jun 20, 2021·Cancer Communications·Haoran WeiXiuying Zhong
Jun 18, 2021·European Journal of Medicinal Chemistry·Wardha ZafarZahid H Chohan
Oct 27, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Lijun Zhang, Wangsen Cao

❮ Previous
Next ❯

Related Concepts

Related Feeds

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.